Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE Immunotherapeutics (PAR: OSE) and partner Veloxis Pharmaceuticals announce ODD for VEL-101
Published by Arron Aatkar, PhD

OSE Immunotherapeutics, and its partner Veloxis Pharmaceuticals, have announced receipt of orphan drug designation (ODD) for VEL-101, which is in clinical development as a potential maintenance therapy for patients following kidney transplantation. This has several development and commercial advantages, including: tax credits for qualified clinical trials; exemption from user fees; and the potential for seven years of market exclusivity after approval. While this is a positive milestone, we note that Veloxis is responsible for the programme and, therefore, OSE has little control over how it runs.